VRTX

Vertex Pharmaceuticals
D

VRTX

463.82
USD
-8.60
(-1.82%)
مفتوح الان
حجم التداول
26,386
الربح لكل سهم
18
العائد الربحي
-
P/E
-121
حجم السوق
119,192,414,346
الأفكار والتحليلات
هشام منسي
هشام منسي
منذ 10 أشهر
buy
2024-08-22 05:31
VRTX Chart
المزيد
أصول ذات صلة
ABBV
ABBV
-5.320
(-2.78%)
186.020 USD
AMGN
AMGN
-4.56
(-1.54%)
292.29 USD
BIIB
BIIB
-4.770
(-3.58%)
128.340 USD
BMRN
BMRN
-1.580
(-2.71%)
56.660 USD
GILD
GILD
-2.910
(-2.60%)
109.190 USD
INCY
INCY
-1.610
(-2.30%)
68.380 USD
LLY
LLY
-33.08
(-4.14%)
765.99 USD
REGN
REGN
-23.08
(-4.04%)
547.70 USD
المزيد
الأخبار المقالات

العنوان: Vertex Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.